Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma

Philip Mack, David R Gandara, Alvin H. Lau, Primo N Lara, Martin J. Edelman, Paul H. Gumerlock

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: We evaluated the combination of UCN-01 plus cisplatin and sought to determine how the cell cycle effects of each agent affected the combined response. Cisplatin-induced DNA damage results in cell cycle arrest, primarily at the S and G2 checkpoints, providing the opportunity for DNA damage repair prior to mitosis. Thus, strategies to enhance cisplatin cytotoxicity include attenuation of DNA damage-induced checkpoints. The cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) can potentiate cisplatin activity, likely via abrogation of the S and G2 checkpoints. UCN-01 has additional effects on cell cycling, including induction of an RB-associated G1 arrest. Methods: NSCLC cell lines A549 (wt p53, wt RB), Calul (p53-null, wt RB) and H596 (mt p53, RB-null) were treated with UCN-01 and/or cisplatin with two-drug treatments delivered in alternate sequences. Effects of drug treatment on cell growth, cell cycling, apoptosis and levels and phosphorylation of cell cycle-associated proteins were evaluated. The interaction between the two drugs was assessed using median effect analysis. Results: When UCN-01 preceded cisplatin, growth inhibition was additive or less than additive, as assessed by median effect analysis. In contrast, when NSCLC cells were treated with cisplatin followed by UCN-01, the combination was synergistic. In this treatment sequence, a decrease in the proportion of cells at the G2 checkpoint was confirmed by reduced expression of cyclins A and B and activation of Cdk1. Abrogation of the G2 DNA damage checkpoint and apoptosis were prevalent only in cell populations treated with cisplatin followed by UCN-01 and was markedly enhanced in the cell lines with disrupted p53. Conclusions: These studies indicate that timing of drug administration strongly influences response to cisplatin plus UCN-01 in NSCLC cells, and this is related to the cell cycle-modulatory effects of these agents. Furthermore, this sequence combination was more effective in cell lines with dysfunctional p53. These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity.

Original languageEnglish (US)
Pages (from-to)337-348
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Volume51
Issue number4
StatePublished - Apr 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Cell Cycle
Cells
DNA Damage
Drug therapy
DNA
Cytotoxicity
Pharmaceutical Preparations
7-hydroxystaurosporine
Apoptosis
Cyclin B
Cyclin A
Cell Line
Cell Cycle Proteins
Phosphorylation
Cyclin-Dependent Kinases
Cell growth
Growth
Cell Cycle Checkpoints

Keywords

  • 7-Hydroxystaurosporine
  • Checkpoint abrogation
  • NSCLC
  • p53
  • UCN-01

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. / Mack, Philip; Gandara, David R; Lau, Alvin H.; Lara, Primo N; Edelman, Martin J.; Gumerlock, Paul H.

In: Cancer Chemotherapy and Pharmacology, Vol. 51, No. 4, 01.04.2003, p. 337-348.

Research output: Contribution to journalArticle

@article{6cb2350bc36c4bb4955ec71548388d1a,
title = "Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma",
abstract = "Purpose: We evaluated the combination of UCN-01 plus cisplatin and sought to determine how the cell cycle effects of each agent affected the combined response. Cisplatin-induced DNA damage results in cell cycle arrest, primarily at the S and G2 checkpoints, providing the opportunity for DNA damage repair prior to mitosis. Thus, strategies to enhance cisplatin cytotoxicity include attenuation of DNA damage-induced checkpoints. The cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) can potentiate cisplatin activity, likely via abrogation of the S and G2 checkpoints. UCN-01 has additional effects on cell cycling, including induction of an RB-associated G1 arrest. Methods: NSCLC cell lines A549 (wt p53, wt RB), Calul (p53-null, wt RB) and H596 (mt p53, RB-null) were treated with UCN-01 and/or cisplatin with two-drug treatments delivered in alternate sequences. Effects of drug treatment on cell growth, cell cycling, apoptosis and levels and phosphorylation of cell cycle-associated proteins were evaluated. The interaction between the two drugs was assessed using median effect analysis. Results: When UCN-01 preceded cisplatin, growth inhibition was additive or less than additive, as assessed by median effect analysis. In contrast, when NSCLC cells were treated with cisplatin followed by UCN-01, the combination was synergistic. In this treatment sequence, a decrease in the proportion of cells at the G2 checkpoint was confirmed by reduced expression of cyclins A and B and activation of Cdk1. Abrogation of the G2 DNA damage checkpoint and apoptosis were prevalent only in cell populations treated with cisplatin followed by UCN-01 and was markedly enhanced in the cell lines with disrupted p53. Conclusions: These studies indicate that timing of drug administration strongly influences response to cisplatin plus UCN-01 in NSCLC cells, and this is related to the cell cycle-modulatory effects of these agents. Furthermore, this sequence combination was more effective in cell lines with dysfunctional p53. These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity.",
keywords = "7-Hydroxystaurosporine, Checkpoint abrogation, NSCLC, p53, UCN-01",
author = "Philip Mack and Gandara, {David R} and Lau, {Alvin H.} and Lara, {Primo N} and Edelman, {Martin J.} and Gumerlock, {Paul H.}",
year = "2003",
month = "4",
day = "1",
language = "English (US)",
volume = "51",
pages = "337--348",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma

AU - Mack, Philip

AU - Gandara, David R

AU - Lau, Alvin H.

AU - Lara, Primo N

AU - Edelman, Martin J.

AU - Gumerlock, Paul H.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Purpose: We evaluated the combination of UCN-01 plus cisplatin and sought to determine how the cell cycle effects of each agent affected the combined response. Cisplatin-induced DNA damage results in cell cycle arrest, primarily at the S and G2 checkpoints, providing the opportunity for DNA damage repair prior to mitosis. Thus, strategies to enhance cisplatin cytotoxicity include attenuation of DNA damage-induced checkpoints. The cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) can potentiate cisplatin activity, likely via abrogation of the S and G2 checkpoints. UCN-01 has additional effects on cell cycling, including induction of an RB-associated G1 arrest. Methods: NSCLC cell lines A549 (wt p53, wt RB), Calul (p53-null, wt RB) and H596 (mt p53, RB-null) were treated with UCN-01 and/or cisplatin with two-drug treatments delivered in alternate sequences. Effects of drug treatment on cell growth, cell cycling, apoptosis and levels and phosphorylation of cell cycle-associated proteins were evaluated. The interaction between the two drugs was assessed using median effect analysis. Results: When UCN-01 preceded cisplatin, growth inhibition was additive or less than additive, as assessed by median effect analysis. In contrast, when NSCLC cells were treated with cisplatin followed by UCN-01, the combination was synergistic. In this treatment sequence, a decrease in the proportion of cells at the G2 checkpoint was confirmed by reduced expression of cyclins A and B and activation of Cdk1. Abrogation of the G2 DNA damage checkpoint and apoptosis were prevalent only in cell populations treated with cisplatin followed by UCN-01 and was markedly enhanced in the cell lines with disrupted p53. Conclusions: These studies indicate that timing of drug administration strongly influences response to cisplatin plus UCN-01 in NSCLC cells, and this is related to the cell cycle-modulatory effects of these agents. Furthermore, this sequence combination was more effective in cell lines with dysfunctional p53. These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity.

AB - Purpose: We evaluated the combination of UCN-01 plus cisplatin and sought to determine how the cell cycle effects of each agent affected the combined response. Cisplatin-induced DNA damage results in cell cycle arrest, primarily at the S and G2 checkpoints, providing the opportunity for DNA damage repair prior to mitosis. Thus, strategies to enhance cisplatin cytotoxicity include attenuation of DNA damage-induced checkpoints. The cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) can potentiate cisplatin activity, likely via abrogation of the S and G2 checkpoints. UCN-01 has additional effects on cell cycling, including induction of an RB-associated G1 arrest. Methods: NSCLC cell lines A549 (wt p53, wt RB), Calul (p53-null, wt RB) and H596 (mt p53, RB-null) were treated with UCN-01 and/or cisplatin with two-drug treatments delivered in alternate sequences. Effects of drug treatment on cell growth, cell cycling, apoptosis and levels and phosphorylation of cell cycle-associated proteins were evaluated. The interaction between the two drugs was assessed using median effect analysis. Results: When UCN-01 preceded cisplatin, growth inhibition was additive or less than additive, as assessed by median effect analysis. In contrast, when NSCLC cells were treated with cisplatin followed by UCN-01, the combination was synergistic. In this treatment sequence, a decrease in the proportion of cells at the G2 checkpoint was confirmed by reduced expression of cyclins A and B and activation of Cdk1. Abrogation of the G2 DNA damage checkpoint and apoptosis were prevalent only in cell populations treated with cisplatin followed by UCN-01 and was markedly enhanced in the cell lines with disrupted p53. Conclusions: These studies indicate that timing of drug administration strongly influences response to cisplatin plus UCN-01 in NSCLC cells, and this is related to the cell cycle-modulatory effects of these agents. Furthermore, this sequence combination was more effective in cell lines with dysfunctional p53. These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity.

KW - 7-Hydroxystaurosporine

KW - Checkpoint abrogation

KW - NSCLC

KW - p53

KW - UCN-01

UR - http://www.scopus.com/inward/record.url?scp=0038578347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038578347&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 337

EP - 348

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -